Raymond James & Associates Reduces Holdings in Caribou Biosciences, Inc. (NASDAQ:CRBU)

Raymond James & Associates lowered its stake in Caribou Biosciences, Inc. (NASDAQ:CRBU) by 13.3% during the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 114,864 shares of the company’s stock after selling 17,558 shares during the quarter. Raymond James & Associates owned approximately 0.13% of Caribou Biosciences worth $658,000 as of its most recent filing with the SEC.

A number of other large investors have also recently bought and sold shares of the stock. State Board of Administration of Florida Retirement System lifted its holdings in Caribou Biosciences by 32.0% in the 3rd quarter. State Board of Administration of Florida Retirement System now owns 21,320 shares of the company’s stock valued at $102,000 after purchasing an additional 5,170 shares in the last quarter. Stansberry Asset Management LLC raised its position in shares of Caribou Biosciences by 8.0% in the third quarter. Stansberry Asset Management LLC now owns 77,232 shares of the company’s stock valued at $369,000 after buying an additional 5,737 shares during the last quarter. Exchange Traded Concepts LLC grew its stake in Caribou Biosciences by 34.0% in the 4th quarter. Exchange Traded Concepts LLC now owns 23,924 shares of the company’s stock worth $137,000 after acquiring an additional 6,066 shares during the period. Principal Financial Group Inc. raised its holdings in Caribou Biosciences by 32.8% in the 3rd quarter. Principal Financial Group Inc. now owns 25,198 shares of the company’s stock valued at $120,000 after acquiring an additional 6,227 shares during the last quarter. Finally, Mutual Advisors LLC purchased a new position in shares of Caribou Biosciences during the 3rd quarter worth $83,000. Institutional investors and hedge funds own 77.51% of the company’s stock.

Caribou Biosciences Stock Down 3.3 %

CRBU stock opened at $3.85 on Thursday. The company has a market cap of $347.73 million, a price-to-earnings ratio of -2.66 and a beta of 2.47. The business has a fifty day simple moving average of $5.65 and a 200-day simple moving average of $5.43. Caribou Biosciences, Inc. has a 52 week low of $3.44 and a 52 week high of $8.59.

Caribou Biosciences (NASDAQ:CRBU) last announced its quarterly earnings results on Monday, March 11th. The company reported ($0.39) EPS for the quarter, missing the consensus estimate of ($0.22) by ($0.17). The firm had revenue of $3.56 million for the quarter, compared to analyst estimates of $5.17 million. Caribou Biosciences had a negative return on equity of 31.06% and a negative net margin of 296.05%. As a group, analysts expect that Caribou Biosciences, Inc. will post -1.76 earnings per share for the current fiscal year.

Analyst Ratings Changes

Separately, HC Wainwright raised their price target on Caribou Biosciences from $23.00 to $24.00 and gave the stock a “buy” rating in a research note on Tuesday, March 19th.

Caribou Biosciences Profile

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.